From: Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression
Gene | SNP | Genotype | No. of patients | No. of events | 5-year survival rate (%) | P a | P b | HR (95% CI) | P c |
---|---|---|---|---|---|---|---|---|---|
NPAS2 | rs6542993 | AA | 169 | 63 | 59.0 | Â | Â | 1.00 | Â |
 |  | AT | 229 | 90 | 58.8 |  |  | 1.40 (0.99–1.98) | 0.059 |
 |  | TT | 57 | 29 | 41.6 |  |  | 2.34 (1.45–3.79) | 0.001 |
 |  | AT/TT vs AA |  |  |  | 0.164 | 0.153 | 1.53 (1.10–2.14) | 0.012 |
 |  | TT vs AA/AT |  |  |  | 0.034 | 0.028 | 1.92 (1.25–2.94) | 0.003 |
 |  | Trend |  |  |  | 0.039 | 0.042 | 1.50 (1.18–1.91) | 0.001 |